

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA-700020

Email: shreeganeshbiotechindia ltd@gmail.com

Date: 28th May, 2018

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of
India Limited
Vibgyor Towers, 4th floor, Plot No
C 62, Opp. Trident Hotel Bandra
Kurla Complex, Bandra (E),
Mumbai - 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREGANES

Scrip Name: Shree Ganesh Bio-Tech (India) Limited

Sub: Audited Financial Result for quarter and year ended 31st March, 2018 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

1. Submission of Audited financial result for quarter and year ended on 31st March, 2018 as per AS Format in PDF in accordance with Schedule III format of Companies Act, 2013.
2. Submission of Reconciliation table for Net Profit/Loss.
3. Submission of Reconciliation of Equity.
4. Submission of A declaration on Auditor's Report with unmodified opinion.

Above Audited financial result for quarter and year ended on 31st March, 2018 as per IND AS Format accordance with Schedule III format of Companies Act, 2013 and Submission of reconciliation table for Equity and Net Profit and Loss of the Financial Results for the quarter and year ended on 31st March, 2018 pursuant to the compliance of SEBI Circular Number CIR/CFD/FAC/62/2016 dated July 05, 2016

Kindly take the same on your record and oblige.

Thanking you.

Yours faithfully,
For Shree Ganesh Bio-Tech (India) Limited



Nirav Kumar
DIN: 08045836
Director

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA-700020

Email: shreeganeshbiotechindiaLtd@gmail.com

Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing and Obligation Disclosure) Regulations, 2015.


In compliance to regulation 33(3)(d) of SEBI (Listing and Obligation Disclosure Requirement) Regulations, 2015 as amended by SEBI (Listing and Obligation Disclosure Requirement) (Amendment) Regulations, 2016 and circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

This is to inform you that Statutory Auditor of the company, M/s. Bipin & Co., Chartered Accountants (FRNo. 101509 W) have issued and audit report with unmodified opinion on the Audited Financial Result of the Company for quarter and financial year ended 31st March, 2018.

Kindly take this declaration on your records.

Yours faithfully,

For, **Shree Ganesh Bio-Tech (India) Limited**


Nirav Parmar
DIN: 08045836
Director

Shree Ganesh Biotech (India) Ltd

CIN:-L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata-700020

Email:- shreeganeshbiotechindia@gmail.com

Statement of Audited Financial Results for the Quarter & Year Ended March 31, 2018

(Rs. In lacs)

Sl no.	Particulars	Quarter Ended 31 Mar 2018	Quarter Ended 31 Dec 2017	Quarter Ended 31 Mar 2017	Previous Year Ended 31 Mar 2017	Current Year Ended 31 Mar 2018
	(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	INCOME FROM OPERATIONS					
(a)	Net Sales/Income from Operations (Net of excise duty)	118.18	104.59	247.87	853.67	785.76
(b)	Other Operating Income	-	-	-	-	-
	Total Income from Operations (Net)	118.18	104.59	247.87	853.67	785.76
2	EXPENSES					
(a)	Cost of material consumed	75.03	55.75	374.25	402.14	336.53
(b)	Purchase of stock-in-trade	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	3.06	-	-
(d)	Employee benefit expense	7.36	0.75	1.33	9.81	9.66
(e)	Depreciation and amortization expense	-	-	-	-	-
(f)	Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	20.25	31.44	(186.08)	65.68	89.53
	Total Expenses	102.64	87.94	192.56	477.63	435.72
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	15.54	16.65	55.31	376.04	350.04
4	Other Income	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	15.54	16.65	55.31	376.04	350.04
6	Finance Costs	-	-	(1.18)	2.72	-
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	15.54	16.65	56.49	373.32	350.04
8	Exceptional Items	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	15.54	16.65	56.49	373.32	350.04
10	Tax Expense	-	-	-	-	-
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	15.54	16.65	56.49	373.32	350.04
12	Extraordinary items (net of tax)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12)	15.54	16.65	56.49	373.32	350.04
14	Paid-up equity share capital (Face Value of Rs. 10/- each)	183.12	183.12	183.12	183.12	183.12
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	667.80	1,017.84
16.i	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised):					
(a)	Basic	0.85	0.91	3.08	20.39	19.12
(b)	Diluted	0.85	0.91	3.08	20.39	19.12
16.ii	Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised):					
(a)	Basic	0.85	0.91	3.08	20.39	19.12
(b)	Diluted	0.85	0.91	3.08	20.39	19.12



Shree Ganesh Biotech (India) Ltd

CIN:-L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata-700020

Email:- shreeganeshbiotechindia@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 31st March, 2018	As at 31st March, 2017
Particulars		Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	0.11	-
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	Financial assets		
	Investments	-	-
	Loans	-	-
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	-	-
	Sub-total - Non-Current Assets	0.11	-
2	Current assets		
	Inventories	-	-
	Financial assets		
	Investments	-	-
	Trade receivables	1,351.82	1,241.77
	Cash and cash equivalents	1.52	0.88
	Bank balances other than Cash and Cash equivalents above	1.29	1.86
	Loans, Current	1,278.33	700.00
	Other financial assets	-	-
	Other current assets	3.17	-
	Assets classified as held for sale	-	-
	Sub-total - Current Assets	2,636.13	1,944.51
	TOTAL - ASSETS	2,636.24	1,944.51
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share capital	183.12	183.12
	Other equity	2,103.84	1,753.79
	Sub-total - Shareholders' funds	2,286.96	1,936.91
2	LIABILITIES		
	Non-current liabilities		
	Financial liabilities		
	Borrowings, non-Current	-	-
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	Sub-total - Non-current liabilities	-	-
3	Current liabilities		
	Financial liabilities		
	Borrowings, Current	19.03	6.30
	Trade payables, Current	-	-
	Other financial liabilities	330.24	-
	Other current liabilities	0.01	1.30
	Provisions	-	-
	Current tax liabilities (net)	-	-
	Sub-total - Current liabilities	349.28	7.60
	TOTAL - EQUITY AND LIABILITIES	2,636.24	1,944.51



Shree Ganesh Biotech (India) Ltd

CIN:-L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata-700020

Email:- shreeganeshbiotechindia@gmail.com

Notes:

1. The Reconciliation of profit after tax for the quarter ended on 31st March, 2018 between Ind-AS Compliant results with reference to previous Indian GAAP results are given below:-

		(Rs. In lacs)
Sl no.	Particulars	Quarter Ended 31 Mar 2018
	Profit/Loss after tax reported in previous Indian GAAP	15.54
1	<u>Expenses</u> Changes in Financial Assets and Liabilities -(Net of tax)	-
2	<u>Income</u> Changes in Financial Assets and Liabilities -(Net of tax)	-
3	<u>Other Comprehensive Income</u> Changes in Other Comprehensive Income (Net of tax)	-
	Total Comprehensive Income as per IAS	15.54

2. Equity Reconciliation As At 31st March 2018

		(Rs. In lacs)
Sl no.	Particulars	Quarter Ended 31 Mar 2018
	Equity as per IGAAP	183.12
1	Proposed Dividend and Tax on dividend	-
2	Fair valuation of investment and Impact of derivative accounting	-
3	Discounting on Long Term provisions/liabilities	-
4	Actuarial loss on Defined benefit plans	-
5	Fair valuation of ESOP	-
6	Deferred Tax impact on (2) to (5)	-
7	Fair valuation of Debt instrument through Other Comprehensive Income (Net of Deferred Tax)	-
	Equity as per Ind AS	183.12

- 3 The format of Quarterly results are prescribed in SEBI circular Ref. CIR/CFD/FAC/62/2016 dated July 05,2016 has been modified to comply with requirements of SEBI's circular dated 5th July, 2016, Ind - AS and Schedule III (Division II) of Companies Act, 2013 applicable to companies that are required to comply with IND-AS.
- 4 Figures of Quarter ending 31/03/2018 are the balancing figures between audited figures for the full financial year and published year to date figures up to the third quarter of the financial year of the company.
- 5 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 28, 2018. The Statutory Auditors have carried out a limited review of the above financial result.
- 6 Company has only one segment and hence no separate segment result has been given.
- 7 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 8 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board
For Shree Ganesh Biotech (India) Ltd

Place : Kolkata
Date : 28th May, 2018

